Patents by Inventor Barbara M. Bryant

Barbara M. Bryant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EZH2 INHIBITOR-INDUCED GENE EXPRESSION
    Publication number: 20210161883
    Abstract: Provided herein are methods of treating subjects characterized as having a gene signature that is indicative of EZH2-inhibitor response, methods for determining said gene signature, and methods of determining which subjects may be responsive to cancer treatments based on said gene signature.
    Type: Application
    Filed: July 10, 2018
    Publication date: June 3, 2021
    Inventors: William D. Bradley, Barbara M. Bryant, Patrick Trojer
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 9963747
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: May 8, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George J. Mulligan
  • METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY
    Publication number: 20170023577
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: March 25, 2016
    Publication date: January 26, 2017
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 9500656
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: November 22, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
  • ASSESSMENT OF CHROMOSOMAL ALTERATIONS TO PREDICT CLINICAL OUTCOME OF BORTEZOMIB TREATMENT
    Publication number: 20160312309
    Abstract: Disclosed herein are chromosomal loci associated with clinical outcome to treatment for multiple myeloma. Genome-wide changes observed in myeloma relate to prognosis and treatment response to a proteasome inhibitor. Compositions and methods are provided to assess DNA copy number at corresponding to markers of loci and genes found thereon which are amplified or deleted, overexpressed or underexpressed in myeloma tumors to predict response to treatment, time-to-progression and survival upon treatment.
    Type: Application
    Filed: July 8, 2016
    Publication date: October 27, 2016
    Inventors: Barbara M. Bryant, Hadi Danaee, George J. Mulligan
  • METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH CANCER THERAPY
    Publication number: 20150252430
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 10, 2015
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George J. Mulligan
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 8889354
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: November 18, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George J. Mulligan
  • METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH CANCER THERAPY
    Publication number: 20130013334
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: August 31, 2012
    Publication date: January 10, 2013
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 8278038
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: October 2, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
  • Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
    Publication number: 20100086922
    Abstract: Disclosed herein are chromosomal loci associated with clinical outcome to treatment for multiple myeloma. Genome-wide changes observed in myeloma relate to prognosis and treatment response to a proteasome inhibitor. Compositions and methods are provided to assess DNA copy number at corresponding to markers of loci and genes found thereon which are amplified or deleted, overexpressed or underexpressed in myeloma tumors to predict response to treatment, time-to-progression and survival upon treatment.
    Type: Application
    Filed: May 27, 2009
    Publication date: April 8, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Hadi Danaee, George J. Mulligan
  • Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
    Publication number: 20090181393
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: December 16, 2008
    Publication date: July 16, 2009
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh
  • Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
    Publication number: 20040156854
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: December 4, 2003
    Publication date: August 12, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh